MSD’s truth about the Januvia agreement breakdown

Since the consigned pharmaceutical company of ‘Januvia(generic name: sitagliptin),’ a DPP-4 inhibitor recording KRW 150 billion annual sales with its single and complex drugs, was recently changed, severe fluctuation occurred. 

Through <Doctors News> on the 18^th, MSD Korea unveiled opposition to the situation in which the MSD Korea’s low commission was the reason for the breakdown of the agree...